In BLCA, one of our most significant findings was increased expression of KRT17, a gene associated with a cytoskeletal signaling pathway, glucocorticoid receptor regulatory network, and MHC class II receptor activity (Wu et al., 2021; Li et al., 2021). The gene discussed is NR3C1; the disease is bladder transitional cell carcinoma.